Swiss pharmaceutical firm Roche Holding AG and Cipla Ltd has begun selling a covid-19 antibody drug cocktail to treat non-hospitalized patients whose infection has risk of turn severe, on Monday. Roche Pharma India will import the cocktail which will then marketed and distributed through Cipla.
The drug has been developed by New York-based Regeneron Pharmaceuticals Inc., comprises of two antibodies casirivimab and imdevimab- this cocktail is a mix of two or more unique biological drugs that act like human antibodies to help fight off infection.
The cocktail of two dosage will cost at Rs.119,500. The drug giants are optimistic that in India the cocktail can help in minimizing hospitalization, ease the burden on healthcare systems and help the patients to treat virus before it turn severe.
In total, the antibody drug cocktail can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India can treat two patients. The second batch will be made available by the middle of June.
The cocktail follows an emergency authorisation from the Drugs Controller General of India earlier this month.